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Abstract
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trials. Social and behavioural
factors related to HIV transmission require examination in each setting where these trials are considered. As part of this, several
countries have also recently begun preparatory research investigating relevant social and behavioural issues. There is a need for a
review of the literature to help focus such research efforts in Sub-Saharan Africa.
Objective: To examine key social and behavioural issues that may impact on the conduct of  HIV vaccine efficacy trials in sub-
Saharan Africa.
Design: Literature review
Methods: Major databases (PubMed, PsychInfo, EBSCOhost, and AIDSline) were searched for literature that discussed social and
behavioural issues related to HIV vaccine trials. Three areas are highlighted as being particularly significant for HIV vaccine research:
(1) willingness to participate in future HIV vaccine efficacy trials, (2) retention of participants in studies, and (3) sexual risk reporting
during trials. For each of these topics, major findings from both developed and developing countries are described and avenues
for further research are discussed.
Results: There are few data from Sub-Saharan Africa regarding willingness to participate in HIV vaccine trials. Data on participant
retention rates varies widely, and maintaining large cohorts of  individuals within Phase III trials presents an important challenge.
In addition, the possible impact of trial participation on sexual disinhibition, and response bias on sexual risk-reporting remain
as issues for HIV vaccine trials in African contexts.
Conclusions: Social and behavioural research forms an important part of preparations for HIV vaccine efficacy trials, and there is
a clear need for more research of this type in Sub-Saharan Africa. Innovative approaches are required to address issues such as
willingness to participate in vaccine research, participant retention during efficacy trials, and the accurate reporting by participants of
sexual risk behaviours.
Key words: Africa, HIV, vaccines, clinical trials, preparation, behaviour, review
African Health Sciences 2005;5(3):198-206
Correspondence author:
Joalida Smit,
MRC Unit for Anxiety and Stress Disorders,
Department of  Psychiatry,
University of Stellenbosch,
PO Box 19063, Tygerberg, 7505
Email: smit@sun.ac.za and djs2@sun.ac.za
Correspondence author:
Joalida Smit,
MRC Unit for Anxiety and Stress Disorders,
Department of  Psychiatry,
University of Stellenbosch,
PO Box 19063, Tygerberg, 7505
Email: smit@sun.ac.za and djs2@sun.ac.za
Introduction
More than twenty years after the start of the epidemic,
HIV/AIDS remains one of the most important
threats to health around the globe.1  Sub-Saharan
Africa is heavily affected by the epidemic with 25
million people currently infected and an estimated 3
million new infections every year.2  A range of  struc-
tural and personal level factors have been thought
to contribute to the rapid spread of the epidemic in Africa.
Major structural factors include social, economic and
healthcare development3 including reduction of poverty
and gender-based violence.4;5 Individual-level factors
include sexual risk behaviours such as transactional sex,
age of sexual debut, number of sexual partners, and low
condom use.5-7 Despite moderate successes in decreasing
individual-level risk8, and international efforts to address
structural factors9;10, the epidemic continues unabated. In
this light, an affordable and effective HIV vaccine remains
vitally important to curtailing the population-level spread
of infection.
Clinical trials for HIV vaccines include three dis-
tinct phases: Phase I trials are conducted on a small number
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of healthy humans at low risk for HIV infection to
assess safety. Phase II trials use larger numbers
(several hundreds) of low risk individuals to build
on this safety data and also assess immunogenicity.
A range of scientific14;15 and ethical issues16 needs to
be considered before moving to phase III trials, which
is one of the reasons why few such trials have taken
place since the start of HIV vaccine development.1
Phase III HIV vaccine trials are conducted on large
numbers of people (several thousands) at high risk
for HIV infection which is currently defined as an
HIV incidence rate of 2% or more.17 These trials
usually take a number of years to complete and
require participants to return for frequent HIV tests
and immunizations.17
Despite acknowledging the need for an
HIV vaccine, progress has been slow for many
resource-poor countries.1;11 Of  the phase I and II
HIV vaccine trials that have taken place globally,
most have been conducted in the United States (US)
and Europe with only four phase I and II trials
completed, or currently in progress in sub-Saharan
Africa (see also www.iavi.org for list of  preventative
trials to date).1  The first phase III HIV vaccine trials
have recently been completed in North America
and Thailand (AIDSVAX B/B and AIDSVAX B/
E, respectively; VaxGen Inc, Brisbane, CA, USA).12
Thailand has also been the only developing country
that has been part of a phase III trial, and has also
had more phase I and II trials than any other
developing country.13
Phase III HIV vaccine trials to date have
largely focused on sub-groups most at risk for HIV
infection, such as commercial sex workers (CSW),
intravenous drug-users (IDU), and men who have
sex with men (MSM).  The AIDSVAX B/B trial
(North America) recruited mainly MSM and the
AIDSVAX B/E study (Thailand) focused on
prevention against blood-borne infection in IDU.12
These trials therefore targeted specific populations
known to be at high risk for HIV infection. In
contrast, the epidemic in sub-Saharan Africa is most
severe in heterosexual men and women2;18 who may
not consider themselves to be at high risk for HIV
infection and perceive obvious benefits to
volunteering for phase III trials. Sub-Saharan Africa
is also characterised by great social, economic and
political diversity, with high rates of  migration19,
political unrest20, a lack of sustained, stable infras-
tructure20;21, and low literacy levels22. In many res-
pects these factors present a challenge to the conduct
of  phase III vaccine trials.
Moreover before the first phase III trials
commenced a range of issues were discussed in the
literature pertaining to both developed17;23;24 and less-
developed countries. 25-28 While the AIDSVAX trials refuted
many of these concerns29;30 they remain important in
countries where trials have not taken place. Key issues
addressed by these studies include:
a) whether it will be possible to recruit and retain the
large numbers of at-risk individuals over long time-
periods as required for phase III trials31-34
b) whether high-risk individuals from the general po-
pulation be willing to enroll in these trials, 32;33 and
c) whether trial participation will result in an increase,
rather than decrease in sexual behaviour due to a
false sense of protection by the vaccine.35;36
Researchers working in HIV vaccine trials describe
these and related issues using the collective term social and
behavioural issues. Given the importance of  an effective HIV
vaccine for addressing the HIV/AIDS epidemic in sub-
Saharan Africa, and the growing movement to test
experimental HIV vaccines in different parts of the conti-
nent, here we review existing evidence regarding the so-
cial and behavioural issues involved in HIV vaccine trials.
We use this review to help highlight topics that require
attention as part of future research to prepare for
upcoming HIV vaccine trials.
Methods
The aims of this review were to (a) report on the key
findings of social and behavioural research conducted to
date involving HIV vaccine trials; (b) to use these findings
to identify the important topics emerging from this
literature; (c) to compare major findings from Africa with
the rest of  the world, and (d) to suggest areas for further
research in Africa as part of preparations for Phase III
efficacy trials.
Search strategy
Data for this review were identified by: searches of the
electronic databases Medline (PubMed), PsychInfo,
EBSCOhost and AIDSline. These databases were chosen
because they provide comprehensive coverage of peer-
reviewed social and behavioural research involving HIV/
AIDS.  Search terms used in electronic databases were
“HIV/AIDS”, “ vaccine”, “vaccine trials”, “risk
behaviours”, “reporting” and “trial participation”, with
different combinations of  these search terms used to iden-
tify articles that met the selection requirements. We also
identified materials through references from relevant ar-
ticles and contacting investigators working in this field
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throughout sub-Saharan Africa. Numerous articles
were identified through searches of the extensive
files of  the authors. English and French language
papers were eligible for the review.
Research findings from HIV vaccine
preparedness and clinical trials were then collated
for both developed (United States and Europe) and
developing countries. One-thousand and fifty-nine
articles were found that discussed HIV vaccines and
clinical trials; of these 204 articles discussed issues
related to behaviour and 208 articles discussed
clinical trials in Africa. Only 86 articles discussed HIV
clinical trials in African countries.
Inclusion Criteria
As part of an ongoing programme of social and
behavioural research under the auspices of the South
African AIDS Vaccine Initiative (SAAVI) we
identified three key topics that are particularly im-
portant for work in sub-Saharan Africa to form
the basis for this review:
a) Willingness to participate in future phase III HIV
vaccine trials;
b) Retention during trials; and,
c) Sexual risk behaviour and reporting of risk
behaviour during trials.
Exclusion criteria
The following areas, although considered significant,
were excluded or limited in the review of literature
and subsequent discussion:
a) Ethical issues during HIV vaccine trials are
discussed only as they pertain to the issues above.
The impact of discrimination during trials may
be a major concern in African countries where
HIV-related stigma have been documented.37-42
A number of studies  have examined the impact
of trial-related discrimination,23;43;44 and the reader
is referred to these texts for a full discussion.
b) Economic (site selection, financial impact, etc),
statistical (sample size, trial endpoints) and
scientific concerns (level and type of induced
immunity, host genetics) were excluded from the
review. However the literature in these areas is
comprehensive and the interested reader are
referred to these reviews.45-47
c) Since HIV transmission in sub-Saharan Africa
occurs predominantly in heterosexual populations
this review will focus only on sexual behaviours
pertaining to this population,48-50 and exclude other
   forms of  transmissions such as needle-sharing
during
intravenous drug-use or sexual practices related to MSM,
for example.
Results and Discussion
Willingness to participate in future phase III HIV
vaccine trials
For phase III HIV vaccine trials to be feasible, high risk
groups must endorse and be willing to participate in such
trials.51;52 However, reported Willingness To Participate
(WTP) in phase III HIV vaccine trials have varied greatly
between studies. In America, WTP in future efficacy trials
ranged from 91% in MSM53 to 27% in a mixed group of
MSM, IDU and high-risk women.54 Among army
conscripts,  25 to 30% were willing to participate in
Thailaind,55-57 while 80% endorsed such trials in Uganda.58
Reported WTP in hypothetical trials does not
necessarily guarantee enrolment into an actual trial. An
American study reported that only 29% of those who
indicated “definitely willing” and 16% of those who
indicated “probably willing” to take part in a HIV vaccine
trial during the preparedness study actually enrolled.59
Similarly, less than 50% of  those enrolled in a preparedness
cohort, who stated that they would take part in a phase
III vaccine trial, eventually enrolled into the North American
AIDSVAX trial.52
Reasons for non-participation in trials include
fears that the vaccine may not be safe for humans;53;54;56;60
may cause side-effects44;56-58 or AIDS,54;55 or that they may
be discriminated against.53-56;60 Reported WTP may also
be influenced by negative media reports,61 and by increased
knowledge of  vaccine trials with data suggesting that the
more participants knew about HIV vaccines and clinical
trials, the less likely they were to participate.59;62-64
Despite this, many participants remained willing
to participate in vaccine trials. Selfless aims such as
altruism56;65;66 and a desire to fight AIDS53;58;67 have often
been cited as motivating factors. Material benefits such as
free medical care58 and monetary compensation have also
been reported as important factors, especially in resource-
poor settings.56;57
Studies also examined the differences between
participants who remained positive about participation and
those who eventually changed their minds after receiving
information about the risks involved. These studies found
that those who remained willing reported more risk
behaviour52;54;62;68;69 and were often younger and more
depressed compared to those who declined participation.52
More importantly, WTP has also been associated with low
socio-economic status and education,52;54;62 and with a
greater difficulty in understanding vaccine-related con-
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cepts.68 This raises important ethical questions about
the inclusion of vulnerable populations in clinical
trials.25;70
Measuring willingness to participate
The decision to take part in a HIV vaccine
efficacy trial is embedded within a context of
personal, emotional and cognitive factors. Cross-
sectional studies often strip the answer (willing or
not) from these contexts and does not provide
insight into how different contexts may influence
decision-making.57;58;71 Another limitation is that it
may be less important to know whether someone
is willing or not willing at a particular point in time,
but what factors influence this decision-making
process. For example, it has been suggested that
African people may have entirely different ways of
making decisions about trial participation since their
concept of self is defined in affiliation with the larger
group, compared to Westerners whose decision-
making may primarily be based on individual
terms.27 While this has been widely contested by
others,72 it has encouraged informed consent
procedures to take cultural differences into
account.73;74 Yet, whether and what cultural factors
impact on decision-making related to phase III trial
participation remains uncertain and requires inves-
tigation.
Areas for further research
1.  Data on the willingness to participate in future
     HIV vaccine efficacy trials are required for
    different African countries..
2. Reported willingness must be compared with
actual enrolment into phase I/II trials in the same
study population. This will be important to
ascertain whether stated willingness corresponds
to actual enrolment before commencing to
phase III trials.
3. The relationship between knowledge of HIV
vaccine trials and WTP has not been examined
in countries with low literacy levels.
4. More research needs to focus on the impact of
culture and social context on decision-making
as well as how individual factors (age, gender,
knowing someone with HIV, emotional states)
interact with culture and social factors during
decision-making.
5. Innovative ways to examine and address issues
about participation are required to ensure that
participants make informed decisions.
Retention and attrition
The ability to recruit and retain large numbers of
participants is a key concern in HIV vaccine efficacy trials.24
Before the first phase III trials were conducted, longitudi-
nal studies examined recruitment and retention in a range
of different sub-groups in America.34 These studies
reported the ability to retain between 70 - 90% of partici-
pants between 9 and 18 months after enrollment,31;75 which
suggested that phase III trials would indeed be feasible.
Similarly, studies in Thailand reported high retention rates
- about 90% in CSW, army conscripts and MSM.76 The
retention rates of  the two AIDSVAX trials have not yet
been made available, but early reports suggest that retaining
participants, while possible, were not without difficulties
and required an extensive investment from study staff.12
Retention data from other forms of  HIV
prevention research are highly variable. In studies of HIV
prevention in pregnancy in Uganda, for example, very low
rates of attrition have been maintained over relatively long
periods 77, while researchers working with CSW in Kenya
reported high drop-out rates (up to 33.7% after enrolment)
and a very high attrition rate due to seroconversion (37%
in the first year).78
Reasons for retention and/or attrition
Incarceration, migration and homelessness
constituted major problems in finding participants who
missed their follow-up visits in longitudinal studies of inner
city drug-users in the USA.79;80 The North American
AIDSVAX trial, which also recruited IDU reported similar
reasons for attrition.12 In contrast, in African studies, attri-
tion was associated with higher risk behaviour and fear
of knowing your HIV status in heterosexual population
in Kenya and Tanzania.78;81 This suggests that factors related
to attrition may differ between population groups, and
may require different approaches to retention.
Retention strategies
Sixty recruitment sites were strategically located
across a large geographic region during the North
American AIDSVAX trial. This prevented loss-to-follow-
up due to migration since participants could be transferred
to another recruitment site in a neighbouring area.12 Other
studies have formed alliances with social service agencies
(governmental and other) to track participants12;79 or
provided counselling, assistance with housing and
employment, food parcels, toiletries and small gifts.79;82
However, a concern is that providing incentives for
retention in populations where even basic provisions are
limited may have ethical implications.25 Logistical factors,
such as travelling long distances to trial-sites, inadequate
roads, a lack of public transport and electricity may also
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negatively impact retention in these settings. Retention
strategies require a significant investment in human,
financial and technological resources, which can be
costly and time-consuming. It is therefore imperative
to understand attrition in different context, to be
able to intervene effectively and in a resource-effi-
cient manner during efficacy trials.
Areas for further research
1. Diverse retention rates have been noted across
studies. Research needs to examine what factors
impact on retention.
2. While innovative recruitment and retention
strategies are needed, the ethical implications of
these on vulnerable populations need to be
assessed.
3. It is uncertain what infrastructure, resources
and technology are required to optimize
retention in African contexts.
4. Creative retention strategies need to be piloted
in different settings to determine cost-effective
ways of retaining participants.
Sexual risk monitoring
Apart from the challenge of retaining trial
participants, there is also a concern that participants
in a vaccine trial may increase their risk-taking
behaviour by thinking the vaccine is protective against
infection. A range of studies, including phase I and
II trials, have reported that participants either
increased or stated that they would increase their
risk behaviour if part of a vaccine trial.35;36;65;68;77;83;84
Concerns have been raised that this may lead to a
perverse outcome where phase III HIV vaccine trials
result in more, rather than less HIV infections.36
Related to this, condom distribution and promo-
tion for sexual risk reduction is a necessary
component of HIV vaccine trials, though there is
no evidence to suggest that increasing the availability
or accessibility of condoms alters sexual activity
itself.85
For ethical reasons it is thus essential that
HIV risk behaviours are carefully monitored and
that effective risk reduction procedures are in place
to prevent sexual disinhibition during trials. Apart
from the fact that there is little data available on
sexual disinhibition during trials, another concern is
that the reliability of sexual risk-reporting is
constrained by memory biases and a range of
demand characteristics86, which have been shown
to negatively impact on vaccine preparedness
research in developed countries87 and must also be
addressed in African contexts.
Measuring sexual risk behaviour
Since ethical and practical issues prevent measuring
sexual behaviour through direct observation, research on
sexual behaviour aims to provide conditions that will
facilitate reliable and valid reports. The assumption is that
honest reports are more accurate and will increase when
privacy and anonymity is assured.88;89 Self-administered
questionnaires are thus preferred as they offer more privacy
than face-to-face interviews, but requires a high level of
literacy and familiarity with questionnaire completion.88 In
cases where this is not possible interviews remain the best
method to obtain information of  sensitive behaviours.
However, this method can introduce response biases which
may affect the accuracy of the data.90;91
Social desirability is one of the key biases that can
influence data based on self-report. It refers to self-
presentation, a tendency to present personal information
in a way that will enhance one’s status in interpersonal si-
tuations.90 In HIV research where safe sexual practices may
be considered desirable, participants may thus bias their
responses accordingly, especially when negative outcomes
are feared.86;90;92 Social desirability may also be prominent
when there is a large discrepancy in race, class or social
status between the researcher and respondent, which is
often the case when research is conducted in African
contexts.25;93
Recently computer-assisted self-interviewing
(CASI) has been examined as an alternative method of
assessment to overcome the limitations inherent in the
interviewing process. This involves the use of  a computer
where questions are either visibly displayed or asked by
the computer in an audio-format (called audio-CASI or
ACASI).94 This is useful in low-literacy populations were
respondents can listen to the questions on earphones and
reply by pressing clearly marked keys on the keyboard or
a touch-screen.94;95 This technology has many advantages
compared to paper-and-pencil tests such as increased
privacy, fewer problems related to multi-lingual and low
literacy contexts, and also ensures a fully standardized data-
collection procedure.94-96 CASI or ACASI has been
successfully used in general population surveys,97 as well
as with high-risk groups such as adolescents,94;98 and IDU.99
However, there is still debate whether CASI is more reliable
than pen-and-paper tests or interviews,100 and the
acceptability of  this technology has not been established
in sub-Saharan Africa. A study in Zimbabwe suggested
that unfamiliarity with technology may be a barrier against
effective usage in rural, low literacy populations.96
Cultural and religious beliefs against talking about
sex may however be less responsive to methodological
advancements.90;101  In societies where strong cultural or
religious taboos exist, research on sexual behaviour may
African Health Sciences Vol 5 No 3 September 2005 203
not only be inaccurate, but also considered offen-
sive.102;103 In addition, urbanization may mediate
cultural taboos, resulting in differential levels of
sexual self-disclosure between members of the same
cultural group,90 and more variability in the accuracy
of  sexual risk reporting in these regions.104 Ways to
improve the acceptability of sexual research in these
settings are complex but essential for phase III HIV
vaccine trial preparations.
Areas for further research
1. Longitudinal studies need to examine changes
in self-reported sexual risk behaviour over time
to examine sexual disinhibition and the
effectiveness of  risk reduction counseling.
2. Culturally-attuned ways to examine sexual risk
reporting related to HIV infection are required.
3. More research on CASI, ACASI and other
methods are needed in sub-Saharan Africa to
establish their appropriateness for use in low
literacy populations who may be unfamiliar with
technology.
4. Research needs to establish whether and how
cultural and religious factors impact on sexual
risk disclosure.
Conclusion
Socio-behavioural research is essential in
preparing for HIV vaccine efficacy trials and should
be strengthened in sub-Saharan Africa. Few data
exist on how different cultural, economic and so-
cial contexts may influence the decision to enter a
trial, the reasons for leaving a trial and the honest
reporting of sexual risk behaviour and needs further
investigation.
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